Essential Oils Market Size to Reach $29.52 Bn by 2031 Amid Growing Demand for Aromatherapy and Pharmaceutical Applications, Says Mordor Intelligence

Mordor Intelligence estimates the essential oils market will reach $20.08 billion in 2026 and $29.52 billion by 2031, an 8.10% CAGR. Growth is attributed to aromatherapy expanding into hospitals and workplaces, pharmaceutical interest in potential applications, and rising Asia-Pacific production and consumption; the region’s production and consumption are forecast to grow at a 10.25% CAGR by 2031. Europe remains the largest market by value, while the report describes competition as moderately fragmented.

Analysis

This is a category-growth signal, not evidence of near-term earnings acceleration for IFF, Givaudan or Symrise: the report provides no company-level exposure, pricing, volume or margin data, and essential oils are only one input category within broader businesses. The more investable second-order effect is likely supply-chain capability. If customers require traceable botanical origins, consistent specifications and application-specific testing, firms with reliable grower networks and extraction/testing capacity could defend share and pricing; harvest volatility or tighter quality requirements could instead raise sourcing and compliance costs. Asia-Pacific production growth may increase supply options, but does not guarantee lower input costs if premium, auditable feedstocks remain constrained.

Near term (days), the release is unlikely to warrant a standalone trade. Over 1–3 months, check company disclosures for essential-oil exposure, sourcing commitments, pricing pass-through and customer wins; watch harvest conditions and EU compliance requirements. Over 6–18 months, broader aromatherapy adoption could support ingredient demand, but pharmaceutical use remains exploratory and should not be valued as proven demand. The contrarian risk is treating market growth forecasts as equivalent to listed-company revenue growth. Falsify the constructive view if earnings commentary shows no relevant volume/pricing contribution, sourcing costs pressure margins without pass-through, or customer adoption fails to convert from trials to recurring orders.

Key Decisions for Investors

• No immediate directional position: treat the Mordor forecast as a watch item, not an earnings revision signal for IFF, Givaudan (GIVN) or Symrise (SY1).
• Ahead of the next results, review segment commentary and filings for botanical-ingredient revenue exposure, procurement/contract coverage, pricing pass-through and evidence of recurring healthcare or personal-care customer demand; do not infer these from the market forecast.
• Revisit a long in the exposed ingredient suppliers only if disclosures confirm incremental volumes or pricing and stable margins. A margin decline tied to botanical input costs without offsetting price increases would invalidate that setup.
• Monitor regional harvest disruptions and EU testing/allergen requirements as potential cost and sourcing catalysts; avoid assuming Asia-Pacific capacity growth automatically benefits buyers or incumbents.